Key Points
- Zoetis director Frank Damelio bought 6,650 shares at an average price of $75.39, a purchase worth about $501,344 and increasing his ownership by 44.91% to 21,458 shares.
- Zoetis stock was down 3.4% and opened near its 1-year low of $74.29, far below its 1-year high of $172.23.
- The company recently reported mixed quarterly results, missing EPS and revenue estimates, while analysts currently have a consensus Hold rating with an average price target of $141.25.
Zoetis Inc. (NYSE:ZTS - Get Free Report) Director Paul Bisaro purchased 2,000 shares of the business's stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Zoetis Price Performance
Shares of NYSE:ZTS opened at $74.32 on Thursday. Zoetis Inc. has a twelve month low of $74.29 and a twelve month high of $172.23. The company's 50 day moving average is $114.33 and its 200 day moving average is $121.77. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The company has a market cap of $31.16 billion, a PE ratio of 12.33, a price-to-earnings-growth ratio of 1.26 and a beta of 0.87.
Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same quarter last year, the company posted $1.48 EPS. Zoetis's quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.89 EPS for the current year.
Institutional Investors Weigh In On Zoetis
Hedge funds have recently bought and sold shares of the stock. Global Wealth Strategies & Associates purchased a new stake in Zoetis in the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc purchased a new position in shares of Zoetis during the 4th quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the 3rd quarter valued at approximately $31,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Zoetis during the 1st quarter valued at approximately $28,000. Finally, Lodestone Wealth Management LLC purchased a new position in shares of Zoetis during the 4th quarter valued at approximately $30,000. Hedge funds and other institutional investors own 92.80% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts have commented on ZTS shares. Citigroup started coverage on Zoetis in a research report on Wednesday, April 15th. They issued a "buy" rating and a $145.00 price objective on the stock. Wall Street Zen lowered Zoetis from a "buy" rating to a "hold" rating in a research report on Saturday, May 2nd. William Blair restated an "outperform" rating on shares of Zoetis in a research report on Monday, March 2nd. Weiss Ratings lowered Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, March 27th. Finally, Piper Sandler restated a "neutral" rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $141.25.
View Our Latest Stock Analysis on Zoetis
About Zoetis
(
Get Free Report)
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
